Base editors

| CRISPR Medicine | This is an overview of articles on base editors

Sign-up to weekly Newsletter here.

Base editors

| CRISPR Medicine | This is an overview of articles on base editors

Sign-up to weekly Newsletter here.

Non-small Cell Lung Cancer, NSCLC, (NCT06097962)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Gastric Cancer and Colorectal Cancer, CRC, (NCT07166263)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.  
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541444)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Pediatric Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541405)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.  
Indicator
IND Enabling
Phase I
Phase II
Phase III
Soft Tissue Sarcoma, (NCT06117878)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.  
Indicator
IND Enabling
Phase I
Phase II
Phase III
Gastric Cancer, (NCT06098898)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.  
Indicator
IND Enabling
Phase I
Phase II
Phase III
Refractory Systemic Lupus Erythematosus, SLE, (NCT07083349)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, (NCT06717932)
Sponsors:
CorrectSequence Therapeutics Co., Ltd  
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine